Clinical Trial Update: Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) [Phase 4]

View source ↗

Summary

Phase 4 cardiovascular and renal microvascular outcomes study with linagliptin in type 2 diabetes completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Linagliptin (linagliptin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2019-01-25